Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGBL2 | Q5U5Z8 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CA4 | P22748 | 2/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1634977 | 0.85 | AGBL2 (0.39) | AGBL2CA12CA9KDM4EMAPT | |
| SCHEMBL29009868 | 0.82 | CA1 (0.40) | AGBL2CA1CA2CA4 | |
| SCHEMBL11269548 | 0.81 | CA1 (0.43) | AGBL2CA1CA2CA4 | |
| SCHEMBL15626646 | 0.78 | MAPT (0.46) | AGBL2KDM4EMAPTPOLBMEN1 | |
| SCHEMBL5062588 | 0.77 | PTGS1 (0.40) | AGBL2MAPTPOLBMEN1KMT2A | |
| SCHEMBL3416138 | 0.77 | AGBL2 (0.42) | AGBL2KDM4EMAPTPOLBMEN1 | |
| SCHEMBL5062590 | 0.77 | AGBL2 (0.42) | AGBL2KDM4EMAPTPOLBMEN1 | |
| SCHEMBL1415209 | 0.77 | AGBL2 (0.42) | AGBL2KDM4EMAPTPOLBMEN1 | |
| SCHEMBL28397693 | 0.77 | CA1 (0.45) | CA1CA2CA4MAPT | |
| SCHEMBL17997353 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7033424-B2 | Phase change inks | XEROX CORPORATION (US) | 2006-04-25 | — | — | US | claimed |
| US-20060021546-A1 | Processes for preparing phase change inks | XEROX CORPORATION | 2006-02-02 | — | — | US | claimed |
| EP-1956054-B1 | Phase change ink | XEROX CORP (US) | 2010-11-24 | — | — | EP | disclosed |
| EP-1958993-A1 | Phase change inks containing colorant compounds | Xerox Corporation (US) | 2008-08-20 | — | — | EP | disclosed |
| EP-1956054-A2 | Colorant compounds | Xerox Corporation (US) | 2008-08-13 | — | — | EP | disclosed |
| US-7033424-B2 | Phase change inks | XEROX CORPORATION (US) | 2006-04-25 | — | — | US | disclosed |
| US-20060021546-A1 | Processes for preparing phase change inks | XEROX CORPORATION | 2006-02-02 | — | — | US | disclosed |
| US-20060020141-A1 | Metallized dye | XEROX CORPORATION | 2006-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060020141-A1 | Metallized dye | CDYL, CDY1; CDY1B, CDYL2 | AGBL2 1525/4885CA1 102/4885CA2 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.